The global artificial intelligence (AI) in epidemiology market is forecasted to generate a CAGR of 27.33% over the projection years of 2024-2032. Key drivers facilitating the market's growth include the early detection and surveillance of disease outbreaks, the growing need for predictive modeling to forecast disease trends, and data availability for epidemiological research.
MARKET INSIGHTS
Early detection and surveillance of disease outbreaks play a pivotal role in driving the growth of the global artificial intelligence (AI) in epidemiology market. By leveraging AI-powered algorithms on vast datasets, public health authorities can swiftly identify emerging threats, enabling timely interventions to mitigate the spread of infectious diseases. This proactive approach not only saves lives but also reduces healthcare costs associated with treating widespread outbreaks.
Furthermore, the adoption of AI in epidemiology enhances the efficiency and accuracy of disease surveillance systems, enabling real-time monitoring of population health trends. This capability enables healthcare stakeholders to anticipate potential outbreaks, allocate resources effectively, and implement targeted interventions, thereby minimizing the impact of epidemics on public health and economies.
The increasing integration of AI technologies into epidemiological research and public health infrastructure fosters collaborations between governments, research institutions, and industry players. These partnerships drive innovation in AI algorithms and data analytics, leading to the development of more sophisticated tools for disease detection, prediction, and response. Consequently, the demand for AI solutions in epidemiology continues to surge, fueling the growth of the global market as stakeholders recognize the critical role of early detection and surveillance in safeguarding public health.
REGIONAL INSIGHTS
The global artificial intelligence (AI) in epidemiology market growth examination compiles the geographical study of Europe, Asia-Pacific, North America, and Rest of World. North America is set to be a major region in the global market during the forecast period.
North America boasts a sophisticated healthcare infrastructure with advanced tools like electronic health records (EHRs) and strong data systems, enabling seamless integration and use of AI solutions. The Government Accountability Office (GAO) and the National Academy of Medicine (NAM) are collaborating on an initiative to explore AI/ML applications in healthcare, assessing their impact and identifying key strategies for optimizing their use. This effort significantly accelerates progress in the North America AI in epidemiology market.
COMPETITIVE INSIGHTS
In the competitive landscape of AI in epidemiology, companies are vying to offer innovative solutions leveraging advanced algorithms and data analytics to enhance disease surveillance and prediction. Key players are focused on developing robust AI models that can efficiently analyze vast amounts of healthcare data to provide actionable insights for public health agencies and healthcare providers.
Additionally, partnerships with research institutions and government bodies are crucial for staying ahead in this rapidly evolving market. Additionally, some of the top companies in the global market are Epic Systems Corporation, Microsoft Corporation, Meditech, etc.
Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. PUBLIC-PRIVATE PARTNERSHIP IN AI FOR HEALTH INFECTION PREDICTION & FORECASTING
2.5.2. RISING APPLICATIONS OF AI IN PERSONALIZED MEDICATIONS
2.5.3. INCREASING POPULARITY IN INFECTION PREDICTION AND FORECASTING ON CLOUD-BASED PLATFORMS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. EARLY DETECTION AND SURVEILLANCE OF DISEASE OUTBREAKS
3.1.2. PREDICTIVE MODELING TO FORECAST DISEASE TRENDS
3.1.3. DATA AVAILABILITY FOR EPIDEMIOLOGICAL RESEARCH
3.2. KEY RESTRAINTS
3.2.1. PRIVACY AND ETHICAL CONCERNS REGARDING SENSITIVE PATIENT DATA
3.2.2. DATA QUALITY AND AVAILABILITY CHALLENGES
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN MACHINE LEARNING AND DATA ANALYTICS
4.1.2. EXPANSION OF TELEHEALTH AND REMOTE MONITORING
4.1.3. INTEGRATION OF AI IN PUBLIC HEALTH SYSTEMS
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTES
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
5. MARKET BY DEPLOYMENT
5.1. ON-PREMISE
5.1.1. MARKET FORECAST FIGURE
5.1.2. SEGMENT ANALYSIS
5.2. WEB-BASED
5.2.1. MARKET FORECAST FIGURE
5.2.2. SEGMENT ANALYSIS
5.3. CLOUD-BASED
5.3.1. MARKET FORECAST FIGURE
5.3.2. SEGMENT ANALYSIS
6. MARKET BY APPLICATION
6.1. INFECTION PREDICTION & FORECASTING
6.1.1. MARKET FORECAST FIGURE
6.1.2. SEGMENT ANALYSIS
6.2. DISEASE & SYNDROMIC SURVEILLANCE
6.2.1. MARKET FORECAST FIGURE
6.2.2. SEGMENT ANALYSIS
6.3. MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE
6.3.1. MARKET FORECAST FIGURE
6.3.2. SEGMENT ANALYSIS
7. MARKET BY END USE
7.1. GOVERNMENT & STATE AGENCIES
7.1.1. MARKET FORECAST FIGURE
7.1.2. SEGMENT ANALYSIS
7.2. RESEARCH LABS
7.2.1. MARKET FORECAST FIGURE
7.2.2. SEGMENT ANALYSIS
7.3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
7.3.1. MARKET FORECAST FIGURE
7.3.2. SEGMENT ANALYSIS
7.4. HEALTHCARE PROVIDERS
7.4.1. MARKET FORECAST FIGURE
7.4.2. SEGMENT ANALYSIS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
8.1.3. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
8.1.4. KEY PLAYERS IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
8.1.5. COUNTRY ANALYSIS
8.1.5.1. UNITED STATES
8.1.5.1.1. UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES